Introduction
Yeast infection of the genital and perianal area in women is common Hilton and Wamock, 1975; Willmott, 1975) and according to the report of the Chief Medical Officer for 1975 (Department of Health and Social Security, 1976) the incidence is increasing. This is said to be enhanced by such factors as antibiotics, immunosuppressive drugs, pregnancy, and diabetes (Gardner and Kaufman, 1969) , while even nylon tights have been implicated (Bull, 1969) .
There is however a group of women prone to recurrent attacks of genital and perianal candidosis in whom no obvious provoking factor can be found. These patients have recurring attacks at varying intervals, often for many years causing much distress Presented in part as a Free Communication at the Eighth World Congress of Gynaecology and Obstetrics in Mexico, October 1976 Patients and methods Forty women attending the Westminster Hospital Department of Sexually Transmitted Diseases between 1974 and 1976 were selected for the trial. The criterion for their inclusion was that they had either a history of recurrent 'thrush' for at least one year treated elsewhere each time with antifungal therapy, and confirmed where possible, or had had at least three proved treated clinical attacks of candidosis in the previous six months in the clinic.
In all cases the patients had distressing symptoms of itching or discharge, signs of vulvitis or vaginitis (Carroll et al., 1973) , and yeasts were grown on culture. At each visit oral, vaginal, and rectal swabs were taken with polyester sponge swabs (Oates et al., 1971) . The oral swabs were taken from both sides of the buccal mucosa opposite the first molar tooth. 176
The vaginal swab was taken from the secretions in the posterior fornix and midvaginal epithelium, and a swab was taken from the rectal mucosa through a proctoscope. Smears were stained by Gram's method and examined microscopically for yeasts, and the swabs were cultured in Feinberg-Whittington medium at 37°C for 48 hours. The yeasts cultured were further identified by the germ tube method and sugar fermentation. The pH of the vaginal discharge was measured at each visit with simple narrow range litmus paper* accurate to 05.
As the patients selected had to attend regularly for a year, only those who were seriously distressed by the problem, who appeared reliable, were cooperative, and lived reasonably near were included in the trial. It was hoped these precautions would reduce defaulting to the minimum. A schematic diagram of the trial is shown in Fig. 1 pack. At the end of the four months' treatment they continued to return monthly in the same way for a further six months. Each patient was also given two Sabouraudchloromycetin culture plates to expose at home, one in the bathroom and one in the bedroom, to see if Candida species would grow from the atmosphere.
Results
Forty women entered the trial with 20 allocated to the active treatment and 20 to the placebo treatment. Table la and b shows that both groups were similar in terms of age, duration of recurrent attacks of 'thrush', and duration of the presenting attack. One patient in the placebo group was diabetic.
As some of the patients had attended other clinics for previously proved attacks of 'thrush' the range of number of proved attacks treated at the Westminster Hospital clinic varied in both groups from two to 13.
SYMPTOMS
As the'trial set out to evaluate the effect of a prophylactic treatment for four months, all the patients were free from severe symptoms before beginning the treatment under study. Figure 2 shows the effect of this treatment on severe symptoms for the two groups. It illustrates when each patient either Months developed symptoms so severe that retreatment was required or, if she did not complete the course, when she was last seen free from symptoms. For example, in the placebo group one patient free from symptoms was 'lost' before the prophylactic treatment was started and another was last seen free from symptoms after four months. In the active group, two patients were 'lost' before treatment began and one each was last seen free from symptoms after one, two, four, and seven months. This was in spite of every possible effort made to get the patients to attend. Symptoms have been considered only when severe enough for retreatment as terms such as itching and discharge were thought to be too subjective. Any patient who had used her emergency pack before her visit was considered to have had symptoms severe enough for retreatment even if at the next visit she was then asymptomatic, or the vagina showed no yeasts.
Because of the loss of patients before treatment, the numbers available for statistical analysis were reduced to 19 in the placebo group and 18 in the active group. The most notable feature of Fig. 2 is the pattern during the first four months. During this period 10 of the 19 patients in the placebo group demonstrated symptoms so severe that they required retreatment during this first four months but only one of the 18 patients in the active group required retreatment duting this period. This is statistically highly significant, P<OOl. However, the active group contained two patients lost to follow-up during this time but even if it is assumed that one of these exhibited severe symptoms before the four months elapsed, the difference between the two groups is still statistically significant (Table 2) .
After prophylactic treatment stopped, the patients in the active group began to relapse and required retreatment. At the last follow-up at 10 months, five of the 19 patients in the placebo group and six of the 18 patients in the active group were still symptom-free. However, they are not directly comparable because of the different pattern of follow-up Figure 3 shows the return of the yeasts to the vagina, regardless of symptoms, for the two groups of patients. There is no significant difference between the results of the two groups, P>0-5, Table 3 .
The presence of symptoms, and positive yeast culture results at each patient-visit were recorded (Table 4 ). In both groups severe symptoms occurred with negative culture results and positive results occurred without symptoms. There was no definite relationship between time to reappearance of yeasts and time to symptoms.
RECTAL YEASTS
Fewer than half of the patients with recurrent genital candidosis carried rectal yeasts initially, six out of 19 and eight out of 19 in the two groups. After oral nystatin only one of the six in the first group and two of the eight in the second group still grew yeasts. However, during the four months after oral nystatin the yeasts returned and at the end of this time the number with rectal yeasts was slightly higher than initially, eight out of 19 and 10 out of 19 in the two groups. There was no difference in the rectal yeast carriage rate during the prophylactic treatment between the active and placebo groups.
ORAL YEASTS Thirty-two of the original 40 patients had oral yeasts before treatment and 26 of these had oral yeasts after two weeks' treatment with oral nystatin. There Odds (1977) remarked that an antifungal preparation should be expected to eliminate only the yeasts from the female genital tract. Its success in relieving symptoms depends on those symptoms being caused exclusively by the yeasts. In the trial of antifungal treatment it was expected that the reduction in symptoms would be associated with the reduction in yeasts cultured from the vagina. Therefore, the observed dissociation between symptoms and positive yeast cultures was a surprise. The intermittent clotrimazole treatment undoubtedly reduced symptoms in the patients with recurrent genital candidosis, which was the original aim, but therapy did not affect regrowth of yeasts in the vagina. It could be argued that symptoms were associated with the number of yeast colonies present and that intermittent treatment simply reduced the total colony count below a critical level. However, Mursic (1975) found that patients with or without symptoms could have the same yeast count.
One possibility is that clotrimazole was acting locally on some factor other than the fungus alone. When the treatment stopped, the symptoms returned in many patients but were not always accompanied by the fungus. Mendel and Haberman (1965) commented on this aspect. They studied patients with cultural and clinical cures who returned later with recurrent symptoms, although the cultures were often still negative. They noticed that clinical cures and alleviation of symptoms occurred during therapy when the organisms were still present, and that in some cases the same fungal treatment could relieve those with symptoms in whom no Candida was ever isolated.
These observations suggest Candida is always a secondary invader in the vagina, either combining with an underlying factor to produce symptoms or enhancing the symptoms this factor has already produced. Gardner and Kaufman (1969) referred to this underlying factor as Factor X.
C. albicans as a primary infecting organism does not really fulfil Koch's postulates (Koch, 1890) . It can occur in the vagina without signs or symptoms of disease and the classical signs and symptoms of candidal vaginitis may occur without the isolation of the yeasts (Carroll et al., 1973) . Maibach and Kligman (1962) found it impossible to infect a healthy subject with Candida. Damage was always needed first.
However, one of the most striking features among the patients in the trial and their contacts was the high incidence of non-specific infection. Seventy per cent of the male contacts had non-specific infection during their association with the patients in the trial. In several cases the male contacts of the trial patients were asymptomatic and the urethritis would have been missed if not looked for carefully. A high proportion of the men carried yeasts on the penis confirming earlier results (Davidson, 1977) . Rohatiner (1966) found a similar association with non-specific urethritis and he commented on the possibility of a relationship between Candida and other organisms found in the male or female genital tract. Loh and Baker (1955) while investigating the effect of tetracycline on yeasts in the gut noticed there was a longer and more persistent overgrowth with Proteus species. Then Yamabayashi (1958) Cohen (1969) . More patients in the active treatment group than the placebo group used oral contraceptives, but as yeast regrowth was the same in both groups and the symptoms were less in the active group, there is no evidence that oral contraceptives had any marked influence on these patients.
It has long been stated that Candida is a disease of the diseased. Wilson (1962) believed that it could even indicate underlying disease before this was clinically detectable. Kirkpatrick et al. (1971) considered that treatment directed only to the organism could be predictably inadequate since the 'fertile soil' for Candida persisted in deficient hosts even after elimination of the organism. As a consequence, although the remission with chemotherapy might be complete, it was almost always temporary. The rational approach should be towards the host and not the organism.
It may be that the common factor necessary is some disorganisation of skin or mucous membrane at a cellular level which allows the fungus to become pathogenic. Simple remedies such as preventing self damage might be sufficient-for example, no douching, no vaginal deodorants, no bubble baths. Perhaps the use of simple lubricants such as KY Jelly* in sexual intercourse for those who do not lubricate well, might prevent mechanical damage. However it is most important to consider always the possibility of underlying infections in women with recurrent genital candidosis and in their contacts. 
